Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up
- PMID: 16181238
- DOI: 10.1111/j.1365-2265.2005.02364.x
Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up
Abstract
Objective: To characterize women with hyperprolactinaemia at diagnosis and to assess the effect of treatment after long duration of the disease.
Design: Retrospective chart review.
Patients and measurements: Two hundred and seventy-one women with hyperprolactinaemia at the Karolinska University Hospital, Stockholm, Sweden between 1974 and 2002 were evaluated retrospectively. Criterion for inclusion was elevated S-PRL (> or = 20 microg/l) found on at least two occasions. Secondary hyperprolactinaemia was excluded. The patients were followed for a median time period of 111 (6-348) months. Two hundred and forty patients were treated with dopamine agonists, 17 underwent surgery, seven received radiotherapy and seven were followed without treatment.
Results: Mean age at diagnosis was 31 (+/- 9.5) years and median PRL level was 72 (25-3500) microg/l. Menstrual disturbances were present in 87% of the women of reproductive age and 47% had galactorrhoea. Microadenomas were found in 63%, macroadenomas in 8% and idiopathic hyperprolactinaemia in 29%. Patients with menstrual disturbances had higher PRL levels than women with normal menstrual function (P < 0.001). We found no differences in PRL levels between patients with or without galactorrhoea (P = 0.578). At the end of clinical follow-up, menstrual cycle was normalized in 94% and galactorrhoea disappeared in 94%. In the medically treated patients, median PRL levels decreased from 70 (25-3100) to 13 (0-89) microg/l, (P < 0.0001). Normalization of PRL level was achieved in 71% of the patients and 80% showed a total or partial degree of tumour shrinkage. In the surgically treated patients, 53% had normal PRL levels without medication at follow-up.
Conclusion: Medical treatment was effective in correcting hypogonadism, normalizing PRL levels and reducing tumour size in the majority of the patients after short-term treatment and also in the long run. However, the possibility of transsphenoidal surgery in specific cases must be considered.
Comment in
-
Three decades of clinical follow-up in 271 women with hyperprolactinaemia; macroprolactinaemia should be considered.Clin Endocrinol (Oxf). 2006 Feb;64(2):226. doi: 10.1111/j.1365-2265.2006.02431.x. Clin Endocrinol (Oxf). 2006. PMID: 16430726 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
